Factors associated with variation in utility scores among patients with prostate cancer

Value in Health

Volumn 11, Issue 7, 2008, Pages 1190-1193

  Shimizu, Fumitaka ^a   Fujino, Katsuki ^b   Ito, Yoichi M ^b   Fukuda, Takashi ^b   Kawachi, Yoshio ^c   Minowada, Shigeru ^d   Fujime, Makoto ^a   Ohashi, Yasuo ^b  

^a JUNTENDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Disease specific functions; Prostatic neoplasms; Quality of life; Utilities

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRACHYTHERAPY; COMORBIDITY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HORMONAL THERAPY; HORMONE ACTION; HUMAN; INTESTINE FUNCTION; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SEXUAL FUNCTION; URINARY TRACT FUNCTION;

EID: 53749098181     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00336.x     Document Type: Article

References (15)

1. Han M, Partin AW, Piantadosi S, et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001 166 : 416 19.
2. Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002 11 : 341 53.
3. Fukuhara S, Suzukamo Y. Manual of SF-36v2 Japanese Version. Kyoto : Institute for Health Outcomes & Process Evaluation Research, 2004.
4. Kakehi Y, Kamoto T, Ogawa O, et al. Development of Japanese version of the UCLA Prostate Cancer Index: a pilot validation study. Int J Clin Oncol 2002 7 : 306 11.
5. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000 56 : 899 905.
6. Homma Y, Tsukamoto T, Yasuda K, et al. Linguistic validation of Japanese version of international prostate symptom score and BPH impact index. Jpn J Urol 2002 93 : 669 80.
7. Greenfield S, Apolone G, McNeil BJ, Cleary PD. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care 1993 31 : 141 54.
8. Dolan P, Gudex C, Kind P, et al. Valuing health states: a comparison of methods. J Health Econ 1996 15 : 209 31.
9. Patrick DL, Starks HE, Cain KC, et al. Measuring preferences for health states worse than death. Med Decis Making 1994 14 : 9 18.
10. Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol 2002 12 : 160 78.
11. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 21 : 271 92.
12. Arnesen T, Trommald M. Are QALYs based on time trade-off comparable? - A systematic review of TTO methodologies. Health Econ 2005 14 : 39 53.
13. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for prostate cancer health states in men aged 60 and older. Med Care 2005 43 : 347 55.
14. Krahn M, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer. Med Care 2003 41 : 153 64.
15. Saigal CS, Gornbein J, Reid K, Litwin MS. Stability of time trade-off utilities for health states associated with the treatment of prostate cancer. Qual Life Res 2002 11 : 405 14.